Tuesday, 16th November Clinical Oncology Society of Australia Annual Scientific Meeting 2021

Welcome by COSA President, Fran Boyle                                                                                                        

Welcome to Country

Official opening

• Leveraging opportunities of the pandemic: Optimal cancer care during and beyond COVID-19 - Dorothy Keefe
• The PROMise of Personalised Patient Care. From WHY to HOW - Bogda Koczwara
• Developing a quality framework for the delivery of immunotherapy - Sara Pai

• Co-design: capturing experiences of care to inform system redesign - Theresa Wiseman
• Co-designing for patient centred care - examples from practice - Leah Heiss
• Using routine patient reported data to innovate services for people affected by brain cancer  - Kate Drummond
• What do Patients need from a Patient Organisation?! - Adam Lynch

• The evidence behind lung cancer screening (trial results) - Louis Irving
• Lung cancer screening – are we there yet? Policy perspective - Dorothy Keefe
• GP perspective - Joel Rhee
• The real risk of lung cancer screening is failure to operate - Gavin Wright
• "User-friendly, highly implementable with rigorous adherence to a clinical pathway”: Feasibility of lung cancer screening implementation and rollout in Australia - Nicole Rankin

• Global advances in prehabilitation - Vickie Baracos
• Risk Stratification & Multimodal Prehabilitation for Modifiable Risk to Improve Surgical Outcomes  - Bernhard Riedel
• Exercise prehabilitation prior to cancer surgery. - Favil Singh
• Multidisciplinary Prehab in Action: An Exercise, Nutrition and Psychology perspective.   - Anna Beaumont, Jess Crowe and Christina Prickett

• Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM) - Prachi Bhave
• Safety/Tolerability and Preliminary Antitumour Activity of Sitravatinib Plus Tislelizumab in Patients With Advanced Platinum-Resistant Ovarian Cancer (PROC) - Jeff Goh
• Modelling the societal outcomes of immunotherapy in cancer care in Australia - Darin Kottege
• LEAP-004: updated data for lenvatinib plus pembrolizumab in patients with advanced melanoma and confirmed progressive disease on a prior PD-(L)1 inhibitor - Georgina V Long
• Cancer Stem Cell Gene Signature Defines Response to Immune Checkpoint Inhibitors in Melanoma patients - Nicole A Seebacher

• COVID-19 Restrictions and Radiotherapy: Did the ‘Ring of Steel’ impact the location Victorian patients received their radiotherapy? - Nigel Anderson
• COVID-19 vaccination in patients with solid tumours: development of an Australian position statement - Yada Kanjanapan
• Impact of COVID-19 on health service activity across Victoria - Abi McBride
• CANcer patients’ perspectives on coronavirus VACCination Survey (CANVACCS): results of vaccine willingness and uptake in Victoria. - Mike Nguyen
• Impact of COVID-19 on the delivery of pharmacy services to patients with cancer; regional (Oceania and Asia) response from an international survey - Gail Rowan
• Changes in systemic cancer therapy in Australia during the COVID-19 pandemic: a population-based study - Monica Tang

• Quality Improvement in the era of big data - Michael Hassett
• Unlocking clinical and administrative data for improving cancer outcomes: best practices, missing links and solutions - Maarten IJzerman
• Integrating cohort studies and population-based data to improve cancer prevention and cancer care - Claire Vajdic

• Dietary Strategies for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review - Megan Crichton
• Cost-effectiveness analysis of home-based rehabilitation in inoperable lung cancer - Lara Edbrooke
• Effect of dietetic counselling delivered via telephone or mHealth on quality of life in people with upper gastrointestinal cancer: a 3-arm randomised controlled trial. - Catherine Huggins
• Do exercise oncology guidelines have to be met to obtain improvements in breast cancer outcomes? - Carolina X Sandler
• The Effects of Physical Exercise in the Palliative Care Phase for People with Advanced Cancer: A Systematic Review with Meta-Analysis - Kellie Toohey

• The CRISP Trial: a randomised controlled trial of a risk assessment and decision support tool for risk-stratified colorectal cancer screening in primary care. - Jon Emery
• Association between skeletal muscle mass and quality of life in adults with cancer: a systematic review and meta-analysis - Lauren Hanna
• Nurse-led telephone notification of a prostate cancer diagnosis: Prospective analysis of men's preferences for and experiences from a same-day assessment and diagnostic clinic - Cynthia Hawks
• Translation of oncology Multidisciplinary Team Meeting (MDM) recommendations into clinical practice - Nisali T Wellege
• Using patient reported outcome measures in a colorectal cancer setting: views of people from culturally and linguistically diverse backgrounds - Justin Yeung

• Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy - Prachi Bhave
• Real-World Three-Year Survival and Clinical Correlates among patients with advanced solid-organ malignancies treated with immune checkpoint inhibitors: Experience from an Australian metropolitan tertiary referral centre - Lauren J Brown
• Immunotherapy improves survival in first-line treatment of extensive-stage small-cell lung cancer. A systematic review and meta-analysis. - Wei Yen Chan
• Improved survival predicted by irAEs on ¹⁸F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma - Sarah Lewis
• Antibiotic Use, Clinical Outcomes, and Systemic Immune Biomarkers in Patients Receiving Immune Checkpoint Inhibitor Therapy - Mitchell S von Itzstein

• Measuring kidney function in cancer patients, problems and issues in onco-nephrology and it’s implications on drug dosing - Ben Sprangers
• Development of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) - Geeta Sandhu
• Clinical perspective of introducing the new guidelines into practice - Michael Michael
• Nephrology pharmacist perspective on the implications of the guideline on clinical pharmacy - Carla Scuderi

4:40 PM Panel discussion including Jolanta Malyszko

• The evolving nature of genetic risk: when new cancer risk information comes to light - Paul James
• Managing patients with unclassified genetic variants and uncertain cancer risk  - Alison Trainer
• Germline mutations in prostate cancer: who, how and why of testing - Ainsley Campbell
• Surveillance in multi-organ cancer predisposition - Mandy Ballinger

• The Telehealth experience pre and post COVID - Craig Underhill
• Growing cancer services in regional NSW - Ruth Jones
• Models of care for RRR and ATSI communities  - Sabe Sabesan
• The WA Country Health Service Cancer Strategy: Partnerships and Innovation for Excellence in Cancer Care - Christine Henneker

4:50PM Panel Discussion

• An Overview of the Need for Patient Reported Measures for Aboriginal and Torres Strait Islander people with cancer - Gail Garvey
• What Matters: Development of a Wellbeing Measure for Aboriginal and Torres Strait Islander Adults - Kate Anderson
• Towards systematic monitoring of the care experiences of Aboriginal and Torres Strait Islander people with cancer - Monica Green
• The importance of family support and assessing supportive care needs of carers for Aboriginal and Torres Strait Islander cancer patients - Daniel Lindsay

• Co-designing cancer education for the Greek community.  - Jane Auchettl
• Experiences and perspectives of cancer patients/survivors, carers, cancer care healthcare professionals, and non-government cancer services, regarding COVID-19 vaccination - Nicci Bartley
• Research and infrastructure priorities for cancer survivorship in Australia - Fiona Crawford-Williams
• Video decision support tool of values discussions between patient-caregiver dyads to promote advance care planning in cancer: Randomised controlled trial - Natasha Michael
• A randomised controlled trial investigating the ability for supervised exercise to reduce treatment-related decline in adolescent and young adult cancer patients. - Claire Munsie
• Evaluating a shared care pathway intervention to reduce chemotherapy outpatients' unplanned presentations to hospital: A randomised controlled trial (RCT) - Kate White

Title - Learning through Patient Experiences – Insights into the Treatment and Management of Advanced Melanoma
Time - 7:00pm - 8:30pm
Chair - A/Prof. Andrew Haydon, Medical Oncologist, The Alfred Hospital – Melbourne
Speakers -

• Prof. Morteza Aghmesheh, Medical Oncologist, Illawarra Cancer Care Centre, Wollongong

• Dr Marcin Dzienis, Medical Oncologist, Gold Coast University Hospital

Description - The patient experience has been transformed with the emergence of immuno-oncology (IO) therapy for the treatment of advanced melanoma. Clinical evidence, real-world experience and perspectives from the patient can provide insights into the treatment and management considerations of advanced melanoma.

During this symposium, our speaker panel will:

• Provide an overview of the evidence for KEYTRUDA® (pembrolizumab) in treating advanced (unresectable or metastatic) melanoma

• Share their perspectives on the experiences of advanced melanoma patients; and

• Impart insights into their treatment and management considerations for advanced melanoma.

• Intestinal Epithelial TLR4 are Crucial to Chemotherapy Toxicity Development - Elise Crame
• Evaluation of the agreement, adoption, and adherence to the Evidence-based guidelines for the nutritional management of adult patients with head and neck cancer among Australian Dietitians - Anna Edwards
• Factors affecting vial yield of parenteral oncology drugs in a metropolitan cancer centre - Matt Roper
• Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: a prospective observational study - Mohsen Shafiei
• Comparison of capecitabine concentration determined by capillary sampling versus venous blood sampling for therapeutic drug monitoring: a pilot study - Mohsen Shafiei
• Uptake of an online psychological therapy program (iCanADAPT-Early) when implemented within a Clinical Pathway in routine cancer care. - Joanne Shaw
• 5-FU Induces acute neurodegeneration followed by persistent neuroinflammation: A new mechanistic hypothesis for the neurological complications of cancer therapy - Courtney B Subramaniam
• Investigation of TLR4 antagonists for prevention of intestinal inflammation   - Janine Tam
• Caring for cancer carers at discharge: Overview of the implementation process and strategies used to embed a carer support intervention into usual practice. - Anthea Udovicich
• Rate of patients receiving second-line treatment for metastatic colorectal cancer in a real-world setting - Katherine Ups
• EGFR mediates and EGF potentiates triple negative breast cancer therapeutic response to cold atmospheric plasmas - Peiyu Wang
• Anakinra is safe in HSCT recipients and reinforces the mucosal barrier to control acute complications of high-dose melphalan: results from the AFFECT-1 (Phase IIA) trial and preclinical efficacy study - Hannah R Wardill
• GeneScreen 5-FU: DPYD Genotype-guided Personalised Fluoropyrimidine Dosing: Feasibility and Implementation - Cassandra White
• Safety of Rapid Infusion Bevacizumab Biosimilar - Julie Adams
• Transition of inpatient oncology patients to supportive or palliative care services; a single institution experience. - Anas Alawawdeh
• Niraparib efficacy and safety in patients with BRCA-mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials - Ashish Banerjee
• 7-day patient-reported toxicity in patients participating in a prospective study of COVID-19 vaccine response in adults with cancer (SerOzNET) - Amy Louise Body
• Rapid startup of a clinical trial due to clinical urgency of the COVID-19 pandemic- lessons for future research. - Amy Louise Body
• The Melanoma Institute Australia (MIA) nomogram for predicting sentinel node positivity in patients with melanoma: influence on clinical practice at MIA - Zoe Boyer
• Heart failure therapies for the prevention of HER2-monoclonal antibody mediated cardiotoxicity: a systematic review and meta-analysis. - Lauren J Brown
• Associations Between Dietary Patterns, Malnutrition, Low Muscle Mass and Sarcopenia in Adults with Cancer: A Scoping Review - Annie R Curtis
• Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC). - Jayesh Desai
• Understanding the current standard of adverse event reporting in exercise oncology trials: a rapid review of the original research supporting exercise and cancer guidelines - Riley Dunn
• The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic literature review  - Anna Edwards
• Microwave Ablation of lung tumors: Appearances may be deceiving - Benedicta Emechete
• Impact of BRAF and KRAS mutation on oncological outcomes in patients with colorectal peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - Michael Flood
• Patterns of use of cannabis in WA cancer patients: a survey - Aesha AG Gandhi
• Does wearable technology improve physical activity in adults with a cancer diagnosis other than breast cancer? A systematic review. - Elise Gane
• A nationwide analysis of demographics, outcomes and health care utilization of HIV and non HIV patients with Head and Neck Cancer - Vedavyas Gannamani
• Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. - Andrew Haydon
• Prevalence of cardiovascular disease risk factors in women undergoing treatment for breast cancer. - Emma Kemp
• Quantifying the benefit of the addition of pertuzumab to standard neoadjuvant chemotherapy plus trastuzumab for HER 2 positive breast cancer – the experience of a single oncology unit - Jun Beng Kong
• Avelumab first-line maintenance + best supportive care vs best supportive care alone for advanced urothelial carcinoma not progressed with first-line chemotherapy: prespecified subgroup analyses from JAVELIN Bladder 100 - Sumit Lumba
• Avelumab first-line maintenance for advanced urothelial carcinoma: analysis of clinical and genomic subgroups from the phase 3 JAVELIN Bladder 100 trial - Sumit Lumba
• The role of inflammatory biomarkers in prediction of chemotherapy response and prognosis for patients diagnosed with pancreatic cancer - Sarah Maloney
• A single centre retrospective chart review study of the use of geriatric assessment for older oncology patients. - Kelly McGrath
• The use of neoadjuvant systemic therapy in early breast cancer as a guide to adjuvant treatment choices: a single institution review - Jessica McKie
• Baseline mutational profiles of patients with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO - Linda Mileshkin
• Patient self-funding of cancer therapeutics - a single centre review of anticancer monoclonal antibody use in solid tumours - Yang Jian Ong
• Pilot results following introduction of a synoptic radiologic report for pancreatic ductal adenocarcinoma (PDAC). - Charles HC Pilgrim
• Nivolumab plus cabozantinib (N+C) vs sunitinib for advanced renal cell carcinoma (aRCC): outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial - David Pook
• Avelumab first-line maintenance for advanced urothelial carcinoma (aUC) in the phase 3 JAVELIN Bladder 100 trial: subgroup analysis by duration of treatment-free interval from end of chemotherapy to start of maintenance - David W. Pook
• Avelumab first-line maintenance plus best supportive care vs best supportive care alone for advanced urothelial carcinoma: JAVELIN Bladder 100 subgroup analysis based on duration and cycles of first-line chemotherapy - Thomas Powles
• Death from diltiazem-ibrutinib interaction - Marissa Ryan
• Oral Mucositis, what have we learnt in the last two decades: A Narrative Review - Ella Shearing
• KRAS G12D mutation subtype is associated with poorer survival in operable pancreatic ductal adenocarcinoma - Henry Shen
• An Observational Study Investigating And Auditing The Safety, Tolerability And Further Efficacy Characteristics Of A Pharmaceutical Grade Cannabis-Based Medicine Prescribed To Eligible Patients For The Management Of Cancer Related Or Non-Cancer Related Pain In General And Specialty Medical Practices Australia-Wide. - Jason Sikali
• An audit of PET scan surveillance for stage III and resected stage IV melanoma treated with adjuvant nivolumab in a tertiary centre in Western Australia. - Alice AT Talbot
• Body composition measurement using bioelectrical impedance analysis scale during the first three cycles of chemotherapy - Sim Yee (Cindy) Tan
• Do specialists use survivorship care plans? A qualitative analysis - Sim Yee (Cindy) Tan
• Retrospective audit on body weight changes for breast cancer survivors attending Sydney Cancer Survivorship Centre clinic - Sim Yee (Cindy) Tan
• Treatment of vaginal atrophy using fractional microablative CO₂ laser in post-menopausal women with breast cancer on aromatase inhibitors: a pilot study - Rebecca Tay
• Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors - Mitchell S von Itzstein
• Developing a personalised professional development program on Advanced Care Planning for oncologists and haematologists - Candice Donnelly
• Patient experiences with a micro-learning program designed to improve self-efficacy managing side effects of chemotherapy - Anna Janssen
• Evaluation of a training package for the clinical verification of systemic cancer therapy by a pharmacist - Kimberley-Ann Kerr
• ReGenerate: The development of a health, wellbeing and survivorship app for adolescent and young adult cancer survivors - Andrew Murnane
• Gippsland Cancer Incidence and the development of foundation data for clinical trials - Hieu Chau
• Australia’s expected cancer prevalence over 5 years and modelled impact health care costs and service delivery - Eleonora Feletto
• Association between patient-reported outcomes and survival in HER2-positive advanced breast cancer: pooled analysis of three clinical trials - Natansh D Modi
• Tasmanians are at high risk of subsequent keratinocyte carcinoma after a first-ever episode - Bruna S Ragaini
• Attitudes, barriers and facilitators to cancer clinical practice guideline adherence: a Systematic Review - Mia Bierbaum
• Men’s preferences for image-guidance in prostate radiation therapy: a discrete choice experiment  - Amy Brown
• Awareness and perceptions of nutrition support in upper gastrointestinal cancer surgery: A national survey of multidisciplinary clinicians - Irene Deftereos
• A 3-year retrospective review of the identification and management of taxane hypersensitivity reactions in a tertiary outpatient oncology centre - Kimchi Do
• Treatment patterns of older patients receiving systemic anti-cancer therapy - Polly H Dufton
• Using population-based cancer data to engage the clinical community: Tumour Summits - Norah Finn
• Rurality and Surgical Management of Small Early Breast Cancer in Western NSW - Jasmine Fyfe
• Monash-Bendigo Teletrials Clinic: facilitating regional patient access to early phase clinical trials - Chloe Georgiou
•  National Cancer Screening Register: Improving access to patient data - Dorota Gertig
• REDCap database: A model to communicate patient information between metro-regional health services - Mayuri Ghatpande
• Staff perspectives on the adoption and feasibility of a clinical pathway for anxiety and depression in cancer care, and mid-implementation adaptations - Marnie Harris
• Australian CANcer patients’ perspectives on coronavirus VACCination Survey (CANVACCS): Short Messaging Service Recruitment Outcomes - Samuel J Harris
• Acceptability and appropriateness of a clinical pathway for managing anxiety and depression in cancer patients: A mixed methods study of staff perspectives. - Sharon He
• Attitudes of professional stakeholders towards the secondary use and sharing of health administrative and clinical trial data: results of a qualitative interview study - Elizabeth Hutchings
• Attitudes towards data sharing and secondary analysis in cancer; results of two questionnaires in professional stakeholders and healthcare consumers - Elizabeth Hutchings
• Implementing a web-based system of screening for unmet needs using patient reported outcomes in people with cancer. - Bogda Koczwara
• Multidisciplinary Team Meetings for Regional Oncology Patients - Kalgoorlie/Esperance - Joann J.L Lee
• Challenges in the implementation of COSA Teletrial model in the Monash-Gippsland Teletrial project - Vi Luong
• Breaking down the Barriers to Fertility Preservation in the Oncology patient via a National Ovarian and Testicular Tissue Transportation and Cryopreservation Service (NOTTCS) - Andrea Martin
• Standardised methodology for systematic review and feasibility testing of evidence-based clinical indicators - Abi McBride
• Barriers and enablers to cancer clinical trial participation and initiatives to improve opportunities for rural cancer patients: A scoping review  - Narelle J McPhee
• Cancer in Primary Care Research Priorities in Australia - Kristi M Milley
• Burnout Amongst Australian Female Oncologists: Exploration of their Lived Experience. - Nicolette L Monkel
• A statewide project to understand current practice and increase awareness of survivorship care in Victoria - Tegan Nash
• Patients’ and their carers’ experiences of lung cancer referral pathway within a regional health service: A qualitative study - Zulfiquer Otty
• Gender representation amongst Principal Investigators of trials run by a large academic collaborative group - Eva Segelov
• Development, Acceptability and Uptake of an on-line anxiety and depression education program for oncology health professionals (ADAPT program) - Joanne Shaw
• From ideal to actual practice: Tailoring a clinical pathway to address anxiety or depression in patients with cancer and planning its implementation across individual clinical services - Heather Shepherd
• Embedding an integrated cancer care model across the Ramsay Health Care network in Australia. - Sue Sinclair
• An agile and systematic approach to Horizon Scanning for the Australian context - Jennifer A Soon
• Should Symptom and Urgent Review Clinic (SURC) be a standard model of care across all cancer services? - Lisa J Taylor
• Impact of a community of practice among cancer clinical nurse consultants - Jenny Thresher
• Improving regional access to clinical trials and implementation of COSA teletrials model by a networked approach: Regional Trials Network Victoria. - Craig R Underhill
• Implementing a Geriatric Oncology Model of Care for Lung Cancer patients - Shalini K Vinod
• Measuring Lung Cancer Quality Indicators at the Multidisciplinary Team level - Shalini K Vinod
• The timeliness of small early breast cancer multi-disciplinary treatment in a large rural centre - Jean-Luc Vrisakis
• A Review of Resource Stratified Guidelines for Cancer – Are They All the Same? Inter-Guideline Concordance for Systemic Treatment Recommendations - Brooke E Wilson
• Home Based Cancer Care  - setting the standard. - Robyn Wilson
• Retrospective audit on corticosteroid-induced hyperglycaemia amongst patients receiving corticosteroids with chemotherapy in a single centre - Nicholas Yeo
• EORTC 1325-MG/KEYNOTE-054 phase 3 trial of pembrolizumab versus placebo for completely resected high-risk stage III melanoma: pembrolizumab crossover and rechallenge following recurrence - Victoria Atkinson
• Interim Analysis of the Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer (EC) Cohorts From the GARNET Study - Ashish Banerjee
• The Time Course of Adverse Events (AEs) During Dostarlimab Treatment in Mismatch Mutation Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer (EC) Patients in the GARNET Trial - Ashish Banerjee
• NeoTrio Trial; Optimal Neoadjuvant Sequencing of Anti-PD1 and BRAF targeting therapy in Resectable BRAF Mutant stage IIIB/C/D Melanoma: Results of Translational Investigations - Jorja Braden
• Weight changes during adjuvant nivolumab for resected melanoma - Michael Cilento
• HLA-I heterozygosity and increased incidence of immune related toxicity among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy - Ngie Chang Law
• Timing of palliative care referral for patients with advanced lung cancer in the immunotherapy era - Lisa Mounsey
• Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): follow-up at 43 months - Danny Rischin
• Safety and efficacy of anti-cancer biosimilars compared to their reference biologics: Systematic Review with Meta-Analysis - Nina K Song
• Health-related quality of life (HRQoL) in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab: analysis of a phase II, open-label clinical trial   - Alexander J Stratigos
• Analysis of the histopathology of resected oligometastatic disease in patients with Metastatic melanoma on immunotherapy who have subsequently achieved complete remission - Sarah Williams
• Immunotherapy for advanced cutaneous squamous cell carcinoma: A retrospective review - Nicholas Yeo
• 1000 voices - cancer and the COVID-19 vaccine - Christie Allan
• Optimal PLAnning of treatment and research of neuroendocrine tumours (NETs) in Australia: the PLANET registry and Patient Reported Outcomes via PLANET App - Meredith Cummins
• Physical Characteristics, Functional Capacity and Symptom Experience of Breast Cancer Patients In Kenya: A Cross-Sectional Investigation - Caitlin Fox-Harding
• Improving lung cancer PROs measurement through patient feedback - Angela Ives
• Understanding the effects of chemotherapy on sleep disturbance in lung cancer patients: a systematic review - Andrew T Jeklin
• Patient Reported Outcomes and Clinical Manifestations of Chemotherapy and Radiation Therapy-Related Mucositis. - Michelle Kang
• Real-Time Symptom Monitoring: Developing a Disease-specific Patient Reported Outcomes (PROs) Tool for Patients with Upper-Gastrointestinal Cancer - Tennille Lewin
• Reducing out-of-pocket expenses and optimising cancer care through bundled packages - Angela Ives
• Prognostic value of patient reported outcomes in advanced gastro-oesophageal cancer: a systematic review - Sayeda SKN Naher
• A Single-Item Measure for Overall Patient-Reported Side Effect Burden in Cancer Trials: A Preliminary Analysis - Jessica Roydhouse
• Using patient reported outcome measures to determine the role of the microbiome in cancer treatment-induced diarrhoea - Kate Secombe
• On the Receiving End: Have patient perceptions of the side-effects of cancer chemotherapy changed since the 20^thcentury? - Janette L Vardy
• Patient-reported outcomes of Medicine Access Programmes: A sub-study of KARMA (Kisqali Access Registry for Metastatic Breast Cancer in Australia) - Vanessa Wong
• Telemedicine in the Context of Covid-19- a Qualitative Study of Cancer Patients and Clinicians. - Dylan DC Chan
• Austin Health Victorian Statewide MR-Linac Service - Stephen Chin
• Victorian Clinical Indications for the MR Linear Accelerator: A Collaborative Public Sector Service Development - Farshad Foroudi
• Statewide Public Radiotherapy Services in Victoria: getting out of service provider silos to improve equity of care and access to optimal treatment - Colin J Hornby
• Consumer Engagement and Victorian Tumour Summits - Janine Scott
• COSA Guidelines - Driving Quality Cancer Pharmacy Services in South Australia - Hayley Vasileff
• Advancing Cancer Pharmacy Practice – SHPA Advanced Training Residency in Cancer Services - Hayley Vasileff
• Enabling equity of access to cancer care via video consultations during the COVID-19 pandemic. - Kate Whitehead
• Conducting a feasibility pilot of a web-based psychosocial program for women with metastatic breast cancer during COVID-19: Recruitment and retention to Finding My Way-Advanced. - Lisa Beatty
• Adherence Rates and Tolerability to a Supervised Virtual Exercise Intervention for Patients with Cancer Cachexia - Kelcey A Bland
• Acupuncture, yoga and mindfulness meditation for weight management after breast cancer: a qualitative study assessing feasibility and acceptability within primary care - Carolyn Ee
• Establishing the first Victorian Head & Neck cancer support group - Tara Gannon
• Evaluating exercise for patients with brain cancer – The BRACE Study  - Gabrielle C Gildea
• Cessation of systemic therapy in advanced lung cancer; Exploring clinician-patient discussion - Kimberley J Omond
• The view from the other side - Sue R Jenkins-Marsh
• Drug use evaluation – assessing nebulised pentamidine usage in a large Australian tertiary hospital  - Melissa Jensen
• Exploring patient characteristics which may predict compliance to exercise oncology recommendations for women receiving chemotherapy for ovarian cancer - Tamara L Jones
• Management of venous thromboembolism in oncology outpatients - Brienna Keates
• Trimethoprim-sulfamethoxazole as Pneumocystis Jiroveci Pneumonia prevention in patients undergoing methotrexate therapy for haematological malignancies: A review of the literature. - Liam King
• A goal-directed therapeutic exercise program in paediatric posterior fossa brain tumour survivors: a case study from the Physical ACTivity in Survivorship (PACTS) randomised controlled trial. - Brooke Kohler
• Psychosocial experiences of people living with advanced colorectal cancer: A qualitative exploration - Chloe Y. S. Lim
• You are allowed to cry without failing to pieces: An exploratory qualitative study to understand the characteristics and underlying mechanisms of resilience in adults with colorectal cancer - Dan Luo
• Factors affecting survival in patients with malignant bowel obstruction receiving palliative care input: a single centre retrospective study - Melani Mahendran
• Retrospective Review of the management of malignant bowel obstruction (MBO) in advanced cancer patients in an Australian acute tertiary referral hospital setting. - Sathya Manoharan
• Voluntary Assisted Dying (VAD) in Victoria - a retrospective case series assessing the application process - Cameron McLaren
• Voluntary Assisted Dying (VAD) in Victoria - a case series of patient characteristics 2019-2021 - Cameron McLaren
• Voluntary Assisted Dying (VAD) in Victoria - a retrospective case series comparing reasons for application with Canada and Oregon - Cameron McLaren
• Feasibility of stepped-care delivery of CBT for persistent fatigue after cancer - Elizabeth Pearson
•   A Digital Model of Care to support pancreatic patients     - Dilu Rupassara
• The prevalence of cachexia and symptom burden in a palliative cohort - Davinia Seah
• Barriers and Enablers to Implementing Telehealth Consultations in Psycho-oncology: building on  COVID-19 experiences - Joanne Shaw
• Lifestyle Medicine after Breast Cancer Treatment: A Pilot Program - Nicole Sirotin
• Knowledge and understanding of the role and feasibility of exercise during and after breast cancer treatment - Ho Wai Derrick Siu
• Pivoting cancer support group leader training in response to the COVID-19 pandemic - Briony Squibb
• What are the characteristics of patients accessing the Home Enteral Nutrition program of a specialist cancer hospital? - Jane Stewart
• The Edmonton Classification System for Cancer Pain in Patients with Bone Metastasis: A cohort study   - Merlina Sulistio
• Development of a Cancer Support Nurse Telehealth Clinic to facilitate symptom management and urgent clinical review. - Kara Sweeney
• Implementing screening for, and management of fear of cancer recurrence, in clinical cancer care - Mei Tran
• The degree of coincidence between medical staffs and bereaved families regarding the presence or absence of terminal delirium, and its related factors - Megumi Uchida
• AYA Can-Sleep: an evidence-based approach to the management of sleep difficulties in young cancer survivors - Emma Vaughan
• A Cost-Consequences Analysis of the SAFE trial: a comparative, effectiveness trial evaluating low versus high level of exercise supervision over a 12-week intervention period for women with breast cancer. - Jessica T Watzek
• Fear of cancer recurrence in informal caregivers: A systematic review of quantitative research - Kyra Webb
• A phase 3, randomized, open-label study (CONTACT-02) of cabozantinib + atezolizumab versus second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) - Arun Azad
• Assessing diet and physical activity with bone, muscle and vascular health during and after radiotherapy for cancer - Jack Dalla Via
• KEYMAKER-U02: Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Melanoma - Georgina V. Long
• SerOzNET: assessing COVID-19 vaccine correlates in cancer patients - Vi Luong
• Definitive randomised double-blind placebo-controlled trial evaluating an oral cannabinoid-rich THC/CBD cannabis extract for chemotherapy-induced nausea and vomiting (CINV) – Trial in progress - Antony Mersiades
• Running a trial remotely. An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: teletrial design and recruitment during COVID-19 - Shakira Milton
• First-line (1L) Maintenance Therapy with Niraparib (nira) + Pembrolizumab (pembro) vs Placebo + Pembro in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): Phase 3 ZEAL-1L Study - Adnan Nagrial
• DuRvalumab with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial. The DREAM3R trial. - Anna Nowak
• CRESTONE – Clinical Study of REsponse to Seribantumab in Tumours with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 monoclonal antibody for Advanced or Metastatic Solid Tumours (MoST CRESTONE in Australia) - Subo Thavaneswaran, BSc, MBBS (Honours), FRACP, MMed PhD
• Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study - Janette L Vardy
• CHALLENGE: A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21) - Janette L Vardy
• KEYNOTE-905/EV-303: A Phase 3 Study of Perioperative Pembrolizumab or Pembrolizumab + Enfortumab Vedotin and Cystectomy Versus Cystectomy Alone in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer - Tammy Hennika